Create a free account to continue

US stocks edge lower as drug companies stumble

NEW YORK (AP) — U.S. stocks are mostly lower Tuesday afternoon, led by a steep decline in drug company shares. Investors are worried that it will become more difficult for the companies to raise drug prices. Energy and materials companies are falling along with the price of oil and precious...

NEW YORK (AP) — U.S. stocks are mostly lower Tuesday afternoon, led by a steep decline in drug company shares. Investors are worried that it will become more difficult for the companies to raise drug prices. Energy and materials companies are falling along with the price of oil and precious metals.

KEEPING SCORE: The Dow Jones industrial dipped five points to 17,224 as of 3:05 p.m. Eastern time. The Standard & Poor's 500 index lost eight points, or 0.4 percent, to 2,012. The Nasdaq composite index fell 27 points, or 0.6 percent, to 4,723. Small company stocks suffered bigger declines than the rest of the market.

Stocks have climbed over the last four weeks following a dismal start to the year. James Paulsen, chief investment strategist for Wells Capital Management, said investors are taking a wait-and-see attitude this week.

"People are kind of re-evaluating where we are," he said. "It's kind of amazing we haven't pulled back a little more."

WATCHING THE FED: Trading has been relatively calm this week as investors wait for the Federal Reserve's Open Markets Committee to meet and make its remarks on interest rates and the economy. The meeting ends Wednesday.

Paulsen said he thinks Wednesday's Consumer Price Index report will be more important than the Federal Reserve's statement because the price data will say more about the state of the economy.

"We ought to be paying attention to the Fed's boss, the economy," he said. "If the economic data gets better, the Fed will raise rates. If it doesn't get better, they won't."

DRUGMAKERS DOWN: Valeant Pharmaceuticals cut its estimates for 2016 and said it could default on some of its debt if it does not complete required financial statements by late April. The Canadian company is under scrutiny from Congress over drug prices and it is being investigated by the Securities and Exchange Commission. The stock plunged $34.98, or 50.7 percent, to $34.04, its lowest price since late 2011.

Acquiring older drugs and raising their prices is a key part of Valeant's business. Other similar companies have tumbled as Congress has raised questions about the practice. On Tuesday Mallinckrodt lost $9.94, or 14.3 percent, to $59.67 and Endo International fell $8.53, or 20.2 percent, to $33.58. Valeant stock has fallen more than 80 percent over the last six months, while Endo is down about 50 percent over that time. Mallincrkodt has dropped about 50 percent since early August.

Drugmaker Eli Lilly fell on concerns surrounding the potential approval of a drug designed to treat dementia caused by Alzheimer's disease. The company said Tuesday it is changing the goal of a late-stage trial, and investors worried the change makes it less likely regulators will approve the drug. The stock gave up $2.74, or 3.7 percent, to $71.17.

TECH TRADES UP: Tech stocks made the biggest gains. Apple led the way, as it rose $2.11, or 2.1 percent, to $104.63 after a Morgan Stanley analyst said first-quarter iPhone sales look stronger than Wall Street had expected.

COMMODITIES CRUNCHED: Energy stocks slumped as oil prices fell sharply for the second day in a row. Benchmark U.S. crude shed 84 cents, or 2.3 percent, to $36.34 a barrel in New York. Brent crude, the benchmark used to price international oils, lost 79 cents, or 2 percent, to $38.74 per barrel in London.

While low oil prices are good news for consumers and many businesses, in recent months stocks have fallen when oil prices have gone down. That's in part because investors fear that the falling prices are a sign the global economy is weakening.

TIGHT-FISTED SHOPPERS: The Commerce Department said retail sales slipped in February, as consumers spent less and remain cautious about the state of the economy in spite of steady hiring. Sales fell 0.1 percent compared with a year earlier, though they improved if gas and auto sales are left out. The government also said sales fell in January, changing an earlier estimate that spending increased.

Spending by consumers makes up 70 percent of the U.S. economy.

WONDERWALL: Outerwall, the company behind Coinstar coin-counting kiosks and Redbox disc-rental kiosks, indicated it may look to sell itself by saying it will seek "strategic and financial alternatives" to boost value for its shareholders. It also doubled its quarterly dividend. The stock added $2.37, or 6.9 percent, to $36.76.

OTHER ENERGY TRADING: Wholesale gasoline slipped 1 cent to $1.41 a gallon. Heating oil fell 2 cents to $1.18 a gallon. Natural gas rose 3 cents, or 1.8 percent, to $1.85 per 1,000 cubic feet.

METALS: Mining companies fell with metals prices. The price of gold fell $14.10, or 1.1 percent, to $1,231 an ounce. Silver sank 26 cents, or 1.7 percent, to $15.26 an ounce. Copper slipped less than 1 cent to $2.23 a pound.

OVERSEAS: The Bank of Japan left its monetary policy unchanged Tuesday but downgraded its assessment of conditions in the world's third-largest economy, citing risks from weaker growth in China and other emerging economies and volatility in financial markets, among other factors. Tokyo's Nikkei 225 lost 0.7 percent and Hong Kong's Hang Seng declined 0.7 percent Seoul's Kospi was off 0.1 percent and the Shanghai Composite Index gained 0.2 percent.

France's CAC-40 lost 0.8 percent and Germany's DAX shed 0.6 percent. Britain's FTSE 100 declined 0.6 percent.

BONDS, CURRENCY: Bond prices held steady and the yield on the 10-year U.S. Treasury note remained at 1.96 percent. The euro edged up to $1.1105 from $1.1097 and the dollar slipped to 113.13 yen from 113.80 yen. The British pound fell to $1.4156 amid renewed jitters about the June popular vote on whether to remain in the 28-country European Union. The pound fell to a seven-year low last month.


AP Markets Writer Marley Jay can be reached at His work can be found at